Department of Medicine Neurology, Dalhousie University, Halifax, Nova Scotia, Canada.
Epilepsia. 2013 May;54 Suppl 2:80-5. doi: 10.1111/epi.12191.
Pharmacoresistant epilepsy is a significant medical problem. The 2nd Halifax International Epilepsy Conference & Retreat identified crucial needs, which if successfully addressed, will aid in paving the way to improved lives for people with pharmacoresistant epilepsy. These are needs: (1) for an evidence-based and dynamic definition of pharmacoresistant epilepsy; (2) for a comprehensive description of the natural history of pharmacoresistant epilepsy; (3) for a comprehensive description of the complications and comorbidities of pharmacoresistant epilepsy; (4) for a rigorous delineation of the epidemiology and socioeconomic impact of pharmacoresistant epilepsy; (5) for clinically meaningful diagnostic and prognostic physiologically based electroencephalography (EEG) biomarkers; (6) for clinically meaningful diagnostic and prognostic anatomically based (MRI Imaging) biomarkers; (7) for biomolecular/biochemical mechanistic understanding of etiopathogenesis for pharmacoresistant epilepsy; (8) for representative animal models of pharmacoresistant epilepsy; (9) for new and effective drugs or other novel treatments for pharmacoresistant epilepsy; and (10) to promote continuing research and research funding targeting pharmacoresistant epilepsy.
耐药性癫痫是一个重大的医学问题。第二届哈利法克斯国际癫痫会议和静修会确定了一些关键需求，如果这些需求得到成功解决，将有助于为耐药性癫痫患者改善生活铺平道路。这些需求包括：（1）对耐药性癫痫进行基于证据和动态的定义；（2）全面描述耐药性癫痫的自然病史；（3）全面描述耐药性癫痫的并发症和合并症；（4）严格划定耐药性癫痫的流行病学和社会经济学影响；（5）具有临床意义的基于生理学的诊断和预后脑电图（EEG）生物标志物；（6）具有临床意义的基于解剖学的诊断和预后磁共振成像（MRI 成像）生物标志物；（7）对耐药性癫痫的病因发病机制进行生物分子/生化机制理解；（8）具有耐药性癫痫的代表性动物模型；（9）针对耐药性癫痫的新药或其他新疗法；以及（10）促进针对耐药性癫痫的持续研究和研究资金。
